Modality
ADC
MOA
STINGag
Target
CGRP
Pathway
Cell Cycle
Epilepsy
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
Feb 2017
→ Sep 2031
Phase 1Current
NCT07243471
1,668 pts·Epilepsy
2017-02→2031-09·Recruiting
NCT07077631
746 pts·Epilepsy
2019-03→2031-01·Recruiting
2,414 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-01-244.8y awayInterim· Epilepsy
2031-09-155.5y awayInterim· Epilepsy
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Recruit…
P1
Recruit…
Catalysts
Interim
2031-01-24 · 4.8y away
Epilepsy
Interim
2031-09-15 · 5.5y away
Epilepsy
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07243471 | Phase 1 | Epilepsy | Recruiting | 1668 | SeizFreq |
| NCT07077631 | Phase 1 | Epilepsy | Recruiting | 746 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP |